AUS
NZ
UK
CA
USA
IND
Highlights
- Orthocell records first US revenue for Remplir™
- Surgeries in Ohio and Florida mark commercial entry
- Positioned for broader rollout in 2025
Orthocell (ASX:OCC), a regenerative medicine company, has officially marked its entry into the US market by generating its first revenue from Remplir™, a collagen-based nerve repair product. This development follows closely on the heels of regulatory clearance in the US, with initial surgeries successfully carried out in Ohio and Florida. These procedures not only initiated revenue generation but also demonstrated operational readiness, confirming fulfilment and billing systems are primed for nationwide scalability.
In a market valued at approximately US$1.6 billion, the company’s swift move from approval to revenue reinforces confidence in its global strategy. Early surgical procedures were conducted in Ambulatory Surgery Centres, offering an ideal platform to train surgeons and introduce Remplir™ into clinical workflows. Orthocell’s broader commercialisation strategy includes leveraging specialist distributors and applying a similar model that proved successful in its Australian rollout.
While the company is not currently part of the ASX 200, its recent progress is attracting interest in the broader market. To stay updated on major Australian-listed companies, including those in the ASX 200.
The June 26 procedure in Ohio marked the first use of Remplir™ in the United States. Follow-up surgeries in Florida quickly followed, highlighting early traction and acceptance within outpatient settings. These procedures are not only revenue-generating but also act as case studies, offering valuable insights for building familiarity among US healthcare professionals.
Orthocell’s rapid transition from regulatory clearance to revenue within three months underlines strong execution across multiple fronts. Key developments include the expansion of the company’s internal teams in sales and medical affairs, increased manufacturing capacity in Australia, and seamless integration with US-based logistics operations.
Backed by robust clinical evidence, Remplir™ supports peripheral nerve repair by promoting improved regeneration and faster functional recovery. With global demand for nerve repair solutions expected to grow—driven by more than two million annual procedures—Orthocell aims to extend its reach well beyond current markets.
With regulatory approvals now secured across Australia, New Zealand, Singapore, and the US, the company is well-capitalised and poised for continued international expansion. A strong cash position and no debt support Orthocell’s strategy to drive growth across the second half of 2025, as it advances Remplir™ and its broader regenerative product line.
